3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
8
Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Leukemia, Myeloid, Acute
4
Hematologic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Pulmonary Disease, Chronic Obstructive
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Leukemia
2
Colonic Neoplasms
2
COVID-19
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stroke
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Methotrexate
11
Busulfan
11
Cytarabine
10
fludarabine
8
Daunorubicin
8
Cyclophosphamide
8
fludarabine phosphate
7
Whole-Body Irradiation
7
Etoposide
7
Tacrolimus
6
Mitoxantrone
5
Melphalan
5
Idarubicin
5
Thioguanine
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Azacitidine
4
thymoglobulin
3
Radiotherapy
3
Filgrastim
3
Early Intervention, Educational
3
Decitabine
3
Cyclosporine
3
Asparaginase
3
Antilymphocyte Serum
3
merphos
2
luspatercept
2
decitabine and cedazuridine drug combination
2
Tretinoin
2
Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Myelodysplastic Syndromes
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts